Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Expert Opinion on Investigational Drugs
|
February 26, 2025
Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Oncoimmunology
|
November 21, 2015
Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D
Elizabeth E Evans, Mark Paris, Ernest S Smith, et al.
International Journal of Molecular Sciences
|
September 10, 2021
Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model
Yilin Mao, Elizabeth E Evans, Vikas Mishra, et al.
Cancer Immunology Research
|
December 6, 2018
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function
Paul E Clavijo, Jay Friedman, Yvette Robbins, et al.
Journal of Neuroinflammation
|
August 6, 2022
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
Elizabeth E Evans, Vikas Mishra, Crystal Mallow, et al.
Molecular Cancer Therapeutics
|
November 24, 2006
C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer
Elizabeth E Evans, Alicia D Henn, Alan Jonason, et al.
BMC Nephrology
|
February 24, 2026
Muscle strength, neuromuscular function, and functional measures across stages of chronic kidney disease
Nicholas A Coker, Michael J Germain, Talat A Ikizler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Elizabeth E Evans, Terrence L Fisher, Vikas Mishra, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|
June 24, 2020
Effects of diet and exercise on adipocytokine levels in patients with moderate to severe chronic kidney disease
Nihal Aydemir, Mindy M Pike, Aseel Alsouqi, et al.
Nature Medicine
|
October 4, 2022
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Expert Opinion on Investigational Drugs
|
February 26, 2025
Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Oncoimmunology
|
November 21, 2015
Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D
Elizabeth E Evans, Mark Paris, Ernest S Smith, et al.
International Journal of Molecular Sciences
|
September 10, 2021
Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model
Yilin Mao, Elizabeth E Evans, Vikas Mishra, et al.
Cancer Immunology Research
|
December 6, 2018
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function
Paul E Clavijo, Jay Friedman, Yvette Robbins, et al.
Journal of Neuroinflammation
|
August 6, 2022
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
Elizabeth E Evans, Vikas Mishra, Crystal Mallow, et al.
Molecular Cancer Therapeutics
|
November 24, 2006
C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer
Elizabeth E Evans, Alicia D Henn, Alan Jonason, et al.
BMC Nephrology
|
February 24, 2026
Muscle strength, neuromuscular function, and functional measures across stages of chronic kidney disease
Nicholas A Coker, Michael J Germain, Talat A Ikizler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Elizabeth E Evans, Terrence L Fisher, Vikas Mishra, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|
June 24, 2020
Effects of diet and exercise on adipocytokine levels in patients with moderate to severe chronic kidney disease
Nihal Aydemir, Mindy M Pike, Aseel Alsouqi, et al.
Nature Medicine
|
October 4, 2022
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
Page
of 2